Simulations Plus, Inc. (SLP)
| Market Cap | 792.63M |
| Revenue (ttm) | 46.17M |
| Net Income (ttm) | 11.67M |
| Shares Out | 20.11M |
| EPS (ttm) | 0.57 |
| PE Ratio | 68.71 |
| Forward PE | 62.11 |
| Dividend | $0.24 (0.61%) |
| Ex-Dividend Date | Oct 22, 2021 |
| Volume | 252,589 |
| Open | 37.93 |
| Previous Close | 37.83 |
| Day's Range | 37.62 - 39.61 |
| 52-Week Range | 36.90 - 90.72 |
| Beta | -0.03 |
| Analysts | Buy |
| Price Target | 64.67 (+64.3%) |
| Est. Earnings Date | Nov 16, 2021 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides ...
Financial Performance
In 2020, SLP's revenue was $41.59 million, an increase of 22.43% compared to the previous year's $33.97 million. Earnings were $9.33 million, an increase of 8.72%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SLP stock is "Buy." The 12-month stock price forecast is 64.67, which is an increase of 64.26% from the latest price.
News
Simulations Plus Announces the University+ Program
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus launched its University+ Program offering students & educators at accredited universities free 1-year access to the company software.
Earnings Preview: Simulations Plus (SLP) Q4 Earnings Expected to Decline
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simulations Plus Announces Cash Dividend
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that its Board of Directors has declared a cash dividend of $0.06 per share to be distributed on Nov. 1, 2021.
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its 4th quarter and fiscal year 2021 results on Mon., Oct. 25, 2021, with a webcast at 5:00pm ET.
Simulations Plus Receives New Grant Award From the FDA
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced a new grant award from the FDA to enhance the predictive power of the mechanistic TCAT model in its flagship GastroPlus.
Simulations Plus Releases ADMET Predictor® (X.3)
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases ADMET Predictor 10.3 (APX.3) with key upgrades to its AIDD Module making it the premier program for AI-driven drug design.
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will be presenting at BofA Securities Tech Solutions for Drug Discovery and Oppenheimer Fall Healthcare Life Sciences conferences.
Simulations Plus Reports Continued Success in Second Phase of AIDD Collaboration with Large Pharmaceutical Company
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports that phase 2 of its AIDD collaboration with a large pharma partner is producing good data validating AIDD in ADMET Predictor.
NMPA's Center for Drug Evaluation Adds Licenses of GastroPlus®
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that China's Center for Drug Evaluation of the NMPA has added GastroPlus licenses for research aiding regulatory reviews.
Simulations Plus (SLP) Q3 Earnings Top, Revenues Miss Estimates
Simulations Plus (SLP) Q3 results are hurt by weakness in Services business, stemming from project delays. Software business revenues witness strong growth.
Here's Why Simulations Plus Stock Is Sliding Today
Investors weren't happy about hiccups that pressured fiscal third-quarter revenue.
Simulations Plus: Q3 Earnings Insights
Shares of Simulations Plus (NASDAQ:SLP) rose fell in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 10.00% year over year to $0.18, which were in l...
Simulations Plus Reports Third Quarter Fiscal 2021 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reported financial results for the 3rd quarter of FY21. Total revenue increased 4% to $12.8 million with software revenue up by 21%.
Simulations Plus (SLP) to Post Q3 Earnings: What's in Store?
Simulations Plus (SLP) fiscal third-quarter performance is likely to reflect gains from strength in its diversified portfolio that includes offerings like GastroPlus, DDDPlus and PKPlus.
Simulations Plus (SLP) to Post Q3 Earnings: What's in Store?
Simulations Plus (SLP) fiscal third-quarter performance is likely to reflect gains from strength in its diversified portfolio that includes offerings like GastroPlus, DDDPlus and PKPlus.
Simulations Plus Earnings Preview
On Monday, July 12, Simulations Plus (NASDAQ:SLP) will release its latest earnings report. Decipher the announcement with Benzinga's help.
Simulations Plus Celebrates 25 Years in Business
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus is celebrating its 25th year in business with a series of events designed to thank our valued clients, employees, and shareholders.
Earnings Preview: Simulations Plus (SLP) Q3 Earnings Expected to Decline
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simulations Plus Sets Date for Third Quarter Fiscal Year 2021 Earnings Release and Conference Call
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its 3rd quarter fiscal year 2021 results on Monday, July 12, 2021, with a webcast at 1:15 pm ET.
Simulations Plus Releases IPFsym version 1A, State-of-the-Art Quantitative Systems Pharmacology (QSP) Software for Id...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of Version 1A of IPFsym, QSP modeling software supporting & accelerating development of new treatments for IPF.
Simulations Plus to Participate in 18th Annual Craig-Hallum Institutional Investor Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will participate in Craig-Hallum's 18th Annual Institutional Investor Conference on June 2, 2021.
Simulations Plus to Present at 16th Annual Needham Virtual Technology & Media Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will participate in the 16th Annual Needham Virtual Technology & Media Conference on Thursday, May 20, 2021.
Simulations Plus Uplisted to The Nasdaq Global Select Market®
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus (SLP) announced today that its securities will be listed on The Nasdaq Global Select Market with the open of business on May 13, 2021
Simulations Plus Releases ADMET Predictor® (X.2)
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases ADMET Predictor APX.2, its flagship machine learning platform with new & enhanced capabilities in discovery PBPK simulations
U.S. FDA Renews Licenses of DILIsym Software
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that the US FDA renewed its licensing to the DILIsym Services division's flagship QST software platform, DILIsym.